Provided by Tiger Trade Technology Pte. Ltd.

TEDA BIOMEDICAL

0.255
0.000
Volume:30.00K
Turnover:8K
Market Cap:544.17M
PE:-5.01
High:0.255
Open:0.255
Low:0.255
Close:0.255
52wk High:0.485
52wk Low:0.114
Shares:2.13B
HK Float Shares:1.44B
Volume Ratio:0.06
T/O Rate:0.00%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.051
ROE:-728.50%
ROA:-14.16%
PB:38.18
PE(LYR):-5.01
PS:0.89

Loading ...

TEDA Biomedical forecasts first-half profit swing on AI healthcare growth

Stock News
·
Aug 18

TEDA Biomedical forecasts RMB290–300 million H1 revenue and swings to RMB7–10 million profit on AI healthcare growth

Bulletin Express
·
Aug 18

Tianjin TEDA Biomedical Engineering Co - Expects Net Profit of RMB7 Mln-RMB10 Mln for Six Months Ended June 30, 2026

THOMSON REUTERS
·
Aug 18

Tianjin TEDA Biomedical Engineering Co - Expects Revenue of Rmb290 Mln-Rmb300 Mln for Six Months Ended June 30, 2026

THOMSON REUTERS
·
Aug 18

Tianjin TEDA Biomedical Engineering Schedules Board Meeting on Half-Year Results, Interim Dividend Decision

Reuters
·
Aug 14

Tianjin Development Names Zhang Wang Chairman, Replacing Teng Fei

Reuters
·
Jul 31

TEDA Biomedical Reports Zero Change in Share Capital for June 2026; Public Float Remains Compliant

Bulletin Express
·
Jul 03

TEDA Biomedical Shifts Principal PRC Office to Beijing’s Zhongguancun Science Park

Bulletin Express
·
Jun 09

TEDA Biomedical Reports No Share Capital Changes in May 2026 Monthly Return

Bulletin Express
·
Jun 03

Tianjin TEDA Biomedical Engineering files directors list with Hong Kong Exchange

Reuters
·
Jun 03

Tianjin TEDA Biomedical Engineering shareholders adopted AGM resolutions

Reuters
·
May 22

TEDA Biomedical: April 2026 Monthly Return Shows Stable 2.13 Billion Share Base and Public-Float Compliance

Bulletin Express
·
May 04

Tianjin TEDA Biomedical Engineering announces annual general meeting

Reuters
·
Apr 30

Tianjin TEDA Biomedical Engineering publishes 2025 annual report

Reuters
·
Apr 30

Tianjin TEDA Biomedical redesignates Xia Alan Zhe as non-executive director

Reuters
·
Apr 30

天津泰达生物聚焦双主业发力,2025年收入增长显著但亏损扩大

Bulletin Express
·
Apr 30

Executive Director Shifts to Non-Executive Role at TEDA BIOMEDICAL

Stock News
·
Apr 30

TEDA Biomedical 2025 Results: Revenue Up 35.7% to RMB 522.97 million, Net Loss Widens to RMB 90.82 million on One-off Impairments

Bulletin Express
·
Apr 01

TEDA Biomedical Reports Stable Share Capital and Sufficient Public Float for March 2026

Bulletin Express
·
Apr 01

TEDA BIOMEDICAL Appoints Lynn Li as Co-CEO

Stock News
·
Apr 01